Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients (ELICE_BD)

This is a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to assess the cognitive effects of lurasidone in bipolar I and II patients (manic depression) who are in

antipsychotics
remission
depressed mood
psychiatric disorder
psychosis
  • 817 views
  • 25 Feb, 2022
  • 9 locations
Comparison of NRX-101 to Standard of Care (Lurasidone) for Bipolar Depression With Subacute Suicidal Ideation and Behavior

NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in

lurasidone
nmda
depressed mood
depressive symptoms
d-cycloserine
  • 20 views
  • 19 Sep, 2022
  • 9 locations
Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU) (MARYLU)

The present longitudinal study aims to investigate the impact of lurasidone treatment in recent-onset psychosis patients. The effects of lurasidone will be studied primarily in terms of

Accepts healthy volunteers
psychosis
lurasidone
  • 0 views
  • 13 May, 2022
  • 1 location
Clinical Efficacy and Safety of Vortioxetine Combined With Mood Stabilizer in the Treatment of Bipolar Disorder Type II Depression (Vortioxetine)

bipolar depression is controversial. The latest Mood Disorders CPG guidelines recommend first-line therapy: quetiapine, lurasidone, lithium, valproate, lamotrigine monotherapy or combination of quetiapine

  • 0 views
  • 19 Aug, 2022
Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients (CARPZ-01)

, improving cognitive functioning is an important treatment goal in people with bipolar disorder. In a recent study, investigators have demonstrated that lurasidone; an atypical antipsychotic was more

  • 0 views
  • 10 May, 2022
  • 2 locations
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression

The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).

  • 0 views
  • 19 Sep, 2022
  • 1 location
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression. Specifically, the investigators will conduct a parallel randomized, double-blind crossover study that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual …

depressive symptoms
bipolar disorder
depressive disorder
antidepressants
depressed mood
  • 58 views
  • 12 Mar, 2022
National Pregnancy Registry for Atypical Antipsychotics

The purpose of the National Pregnancy Registry for Atypical Antipsychotics is to determine the frequency of birth defects among infants exposed to atypical antipsychotics.

Accepts healthy volunteers
atypical antipsychotic
antipsychotics
typical antipsychotic
  • 352 views
  • 30 Jan, 2022
  • 1 location
Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia" (SWITCH)

regimen to monotherapy with lurasidone or to one of the other four most used atypical antipsychotics.

risperidone
olanzapine
antipsychotics
quetiapine
aripiprazole
  • 0 views
  • 21 Jul, 2022
  • 1 location
A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.

(psychiatric services). Schizophrenia patients will be enrolled in a consecutive manner over a period of 6 month into two cohorts according to their prescribing switching treatment: to lurasidone (cohort A

  • 0 views
  • 18 Feb, 2021
  • 10 locations